# OnCo record ponatinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/ponatinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "ponatinib" ;
  schema:name "Ponatinib"@en ;
  schema:description "Ponatinib is the only BCR::ABL1 inhibitor that covers the T315I resistance mutation. In 2024 it became the preferred pill for newly diagnosed Ph-positive ALL."@en ;
  schema:url <https://onco.cc/drugs/ponatinib/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Ponatinib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q198728> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Ponatinib> ;
  onco:status "approved" ;
  onco:modality "Small-molecule kinase inhibitor (pan-BCR::ABL1 incl. T315I)" ;
  schema:alternateName "Iclusig" ;
  onco:approval "US 2012: CML and Ph+ ALL resistant to prior TKIs or with T315I", "US 2024: Newly diagnosed Ph+ ALL with chemotherapy (accelerated)" ;
  onco:acceleratedApproval "US 2012-12-14: Adults with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia resistant or intolerant to TKI therapy or or Philadelphia chromosome positive acute lymphoblastic leukemia resistant or intolerant to prior TKI therapy", "US 2024-03-19: Adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy." ;
  onco:acceleratedApprovalConfirmed "US 2016-11-28: Adults with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia resistant or intolerant to TKI therapy or or Philadelphia chromosome positive acute lymphoblastic leukemia resistant or intolerant to prior TKI therapy" ;
  onco:related <https://onco.cc/biomarkers/bcr-abl1-t315i/> ;
  onco:cancers <https://onco.cc/cancers/all-leukemia/>, <https://onco.cc/cancers/cml-advanced-phase/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/bcr-abl/>, <https://onco.cc/targets/abl1/> ;
  onco:companies <https://onco.cc/companies/takeda/> ;
  onco:terms <https://onco.cc/terms/ph-positive-all/> ;
  onco:trials <https://onco.cc/trials/phallcon/>, <https://onco.cc/trials/nct04233346/>, <https://onco.cc/trials/nct03934372/> .